Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ALL patients' liver toxicities linked to antibiotics, other therapies

Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

Key clinical point: Liver toxicity with pegylated asparaginase (PEG-ASP) may be linked to concomitant chemotherapeutics or antibiotics in ALL.

Major finding: Idarubicin was associated with a higher risk of grade 3 or 4 hepatotoxicity, and vincristine was associated with a borderline risk.

Study details: Retrospective review of 51 PEG-ASP dosing events in 26 adult patients with ALL.

Disclosures: The study was internally funded. The authors reported having no relevant conflicts of interest.

Source: Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

Read the article.

Citation:

Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

This Week's Must Reads

Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

ctDNA may predict survival, treatment response in DLBCL, Kurtz DM et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.78.5246.

Post-discharge rivaroxaban does not change VTE risk, Spyropoulos AC et al. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1805090.

Restrictive transfusion strategy in CV surgery doesn't raise long-term risk, Mazer CD et al. N Engl J Med. 2018 Aug 26. doi:10.1056/NEJMoa1808561

Promise of SGN-CD70A against NHL eclipsed by adverse events, Phillips T et al. Invest New Drugs. 2018 Aug 22. doi: 10.1007/s10637-018-0655-0.